Search Results
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
lines of therapy for small cell lung cancer patients." "For far too long, people living with small cell lung cancer had few options once their first treatment stopped working," said Laurie Fenton Ambrose, co-founder, president, and CEO, GO2 for Lung Cancer. "Today's full approval
More news about: Amgen
Nov 19, 2025, 15:30 ET With a $2.5B Valuation, Function Becomes the New Standard for Health and Launches Medical Intelligence Lab
accessible to more people. The advanced MRI can detect cancers, unruptured aneurysms, endometriosis, signs of stroke, etc., while the CT scan can identify lung cancer, plaque in the heart, etc. All data is integrated into a single intelligent interface, giving each member a personalized view of their health
More news about: Function Health
Nov 19, 2025, 13:27 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Wellcare
Nov 19, 2025, 12:07 ET Latest ACS Lung Cancer Data: Only 1 in 5 Eligible Adults in U.S. Screened for Lung Cancer; 62,000 Lives Over 5 Years Could be Saved if All Eligible Screened
more lung cancer deaths could be prevented (or lives saved) if everyone eligible were screened." Lung cancer is the second most common cancer in the U.S., with around 225,000 new cases diagnosed in 2025, and the leading cause of cancer death, with 125,000 deaths from lung cancer
More news about: American Cancer Society
Nov 19, 2025, 09:55 ET Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
/PRNewswire/ -- New interim data from the IMPAACT 2034 study presented today as a late-breaking oral abstract at the 2025 Union World Conference on Lung Health demonstrates that a single dose of pretomanid, in female children with rifampicin-resistant tuberculosis (RR-TB), was safe, well-tolerated, and
More news about: IMPAACT
Nov 19, 2025, 08:54 ET IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
Lung Cancer Study published in PLOS Once reported that IceCure's cryoablation system combined with radiation therapy successfully treated non-small cell lung cancer ("NSCLC") with 92% disease-specific
More news about: IceCure Medical
Nov 19, 2025, 08:06 ET Ohm and Whipsaw Redefine Wellness Tech with the Ohm Resonance Lamp
vibrations that reinforce the baroreceptor-driven oscillations traveling through the vascular system. As the user enters this state of synchronized heart–lung regulation, the lamp transitions from amber to blue, signaling optimal alignment. Subtle sound cues complete the multisensory loop, transforming complex
More news about: Whipsaw, Inc.
Nov 19, 2025, 07:03 ET Workplace Health 2030: Godrej Industries Group and Global Partners aim to redefine well-being for new era of work
accessible, personal, and actionable. Our core mission is NCD prevention, addressing diseases like Type 2 diabetes, heart disease, cancer, and chronic lung conditions that are overwhelming India's healthcare systems. We've already reached 19 million people by 2024. With strong momentum,
More news about: Godrej Industries Group
Nov 19, 2025, 07:00 ET Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track
More news about: Genprex, Inc.
Nov 19, 2025, 05:03 ET World COPD Day: Lung Association Offers Free Access to Lung Health Navigators to People with COPD Nationwide
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Nov 19, 2025, 05:00 ET Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time
Nov. 19, 2025 /PRNewswire/ -- New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the potential to improve tuberculosis
More news about: TB Alliance
Nov 18, 2025, 23:50 ET Nuvalent Announces Pricing of Public Offering of Common Stock
responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Cautionary Note Regarding Forward-Looking Statements
More news about: Nuvalent, Inc.
Nov 18, 2025, 16:13 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Nov 18, 2025, 16:05 ET TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 37th
More news about: TransMedics Group, Inc.
Nov 18, 2025, 12:10 ET Dynarex Expands Resp-O₂™ Line with Vortex 72 Closed Suction Catheters
patients. Designed for up to 72 hours of use, the Vortex 72 provides continuous suctioning without ventilator disconnection — helping clinicians maintain lung volume, preserve oxygenation, and reduce infection risk during critical care procedures.
More news about: Dynarex Corporation
Nov 18, 2025, 11:06 ET European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor
More news about: Insmed Incorporated
Nov 18, 2025, 11:00 ET European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class
More news about: Insmed Incorporated
Nov 18, 2025, 10:50 ET MiRNA Microarray Kits And Reagents Market Surges to USD 2.45 Billion by 2033, Propelled by 8.5% CAGR - Verified Market Reports®
indication-specific clinical validation in partnership with large academic medical centers or biotech companies for one or two high-value use cases (e.g., lung or colorectal early detection); (c) offer a licensing or co-development route for diagnostic manufacturers to carry the clinical and regulatory load
More news about: Verified Market Reports
Nov 18, 2025, 10:00 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Wellcare
Nov 18, 2025, 09:00 ET TytoCare Integrates With Teladoc Health to Augment Virtual Primary and Urgent Care
integration, Teladoc Health care teams will be able to conduct remote physical exams using TytoCare's handheld device, including lung exams (using TytoCare's AI-powered Lung Sounds Suite, recently listed as a TIME 2025 Best Invention), throat, ear, heart, skin, and temperature assessments. TytoCare's
More news about: TytoCare
Nov 18, 2025, 09:00 ET Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.
access to Roche plasma sample cohorts that will help accelerate development of personalized screening tests for multiple types of cancer, including lung cancer. "We are delighted to deepen our R&D partnership with Roche to enhance our multiomic blood-based cancer screening
More news about: Freenome Holdings, Inc.
Nov 18, 2025, 08:30 ET IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
to surgical tumor removal, today announced that the ProSense® system and cryoprobes for the treatment of malignant or benign tissue of the breast, lung, liver, kidney, and musculoskeletal (bone), including palliative interventions, has been officially registered and approved for distribution by Swissmedic,
More news about: IceCure Medical
Nov 18, 2025, 07:32 ET Medunik USA reaffirms support for Sickle Cell Disease community with uninterrupted supply and Patient-Centered Services
sickle cell anemia. Expert opinion on drug safety 14, 1749-1758, doi:10.1517/14740338.2015.1088827 (2015). National Heart, Lung, and Blood Institute, National Institutes of Health, Sickle Cell Disease,
More news about: Medunik USA
Nov 18, 2025, 07:00 ET Vast Therapeutics Completes First Milestone in Phase 1 Clinical Program
About Bronchiectasis Bronchiectasis is a chronic lung disease that affects approximately 400,000 adults in the United States and several million worldwide. People with bronchiectasis have severe and progressive lung disease characterized by irreversibly damaged dilated bronchial airways
More news about: Vast Therapeutics, Inc.
Nov 18, 2025, 07:00 ET Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
lead drug candidate, REQORSA, and this new patent provides the necessary technology protection applicable to our Acclaim-3 clinical trial in small cell lung cancer," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. "In the Acclaim-3 clinical trial, we are combining
More news about: Genprex, Inc.